These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

404 related articles for article (PubMed ID: 16832839)

  • 1. Alanine aminotransferase as a marker of non-alcoholic fatty liver disease in relation to type 2 diabetes mellitus and cardiovascular disease.
    Schindhelm RK; Diamant M; Dekker JM; Tushuizen ME; Teerlink T; Heine RJ
    Diabetes Metab Res Rev; 2006; 22(6):437-43. PubMed ID: 16832839
    [TBL] [Abstract][Full Text] [Related]  

  • 2. NAFLD as a risk factor for the development of diabetes and the metabolic syndrome: an eleven-year follow-up study.
    Adams LA; Waters OR; Knuiman MW; Elliott RR; Olynyk JK
    Am J Gastroenterol; 2009 Apr; 104(4):861-7. PubMed ID: 19293782
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impact of non-alcoholic fatty liver disease on accelerated metabolic complications.
    Fan JG
    J Dig Dis; 2008 May; 9(2):63-7. PubMed ID: 18419637
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Nonalcoholic fatty liver disease: defining a common problem.
    Gasbarrini G; Vero V; Miele L; Forgione A; Hernandez AP; Greco AV; Gasbarrini A; Grieco A
    Eur Rev Med Pharmacol Sci; 2005; 9(5):253-9. PubMed ID: 16231586
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The central role of the non alcoholic fatty liver disease in metabolic syndrome.
    Hurjui DM; Niţă O; Graur LI; Mihalache L; Popescu DS; Graur M
    Rev Med Chir Soc Med Nat Iasi; 2012; 116(2):425-31. PubMed ID: 23077931
    [TBL] [Abstract][Full Text] [Related]  

  • 6. What are the risk factors and settings for non-alcoholic fatty liver disease in Asia-Pacific?
    Fan JG; Saibara T; Chitturi S; Kim BI; Sung JJ; Chutaputti A;
    J Gastroenterol Hepatol; 2007 Jun; 22(6):794-800. PubMed ID: 17498218
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Nonalcoholic fatty liver disease: a practical approach to evaluation and management.
    Rafiq N; Younossi ZM
    Clin Liver Dis; 2009 May; 13(2):249-66. PubMed ID: 19442917
    [TBL] [Abstract][Full Text] [Related]  

  • 8. An association between non-alcoholic fatty liver disease and polycystic ovarian syndrome.
    Brzozowska MM; Ostapowicz G; Weltman MD
    J Gastroenterol Hepatol; 2009 Feb; 24(2):243-7. PubMed ID: 19215335
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The role of non-alcoholic fatty liver disease in cardiovascular disease.
    Perseghin G
    Dig Dis; 2010; 28(1):210-3. PubMed ID: 20460913
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Non-alcoholic fatty liver disease, the metabolic syndrome and the risk of cardiovascular disease: the plot thickens.
    Targher G
    Diabet Med; 2007 Jan; 24(1):1-6. PubMed ID: 17227317
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical spectrum and natural history of non-alcoholic steatohepatitis with normal alanine aminotransferase values.
    Amarapurkar DN; Patel ND
    Trop Gastroenterol; 2004; 25(3):130-4. PubMed ID: 15682660
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Metabolic and histological features of non-alcoholic fatty liver disease patients with different serum alanine aminotransferase levels.
    Wong VW; Wong GL; Tsang SW; Hui AY; Chan AW; Choi PC; Chim AM; Chu S; Chan FK; Sung JJ; Chan HL
    Aliment Pharmacol Ther; 2009 Feb; 29(4):387-96. PubMed ID: 19035982
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Risk factors associated with nonalcoholic fatty liver disease and its relationship with the hepatic histological changes.
    Rodríguez-Hernández H; Gonzalez JL; Márquez-Ramirez MD; Flores-Hernandez M; Rodríguez-Morán M; Guerrero-Romero F
    Eur J Gastroenterol Hepatol; 2008 May; 20(5):399-403. PubMed ID: 18403941
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Perspective: nonalcoholic fatty liver disease and cardiovascular risk.
    Nestel PJ; Mensink RP
    Curr Opin Lipidol; 2013 Feb; 24(1):1-3. PubMed ID: 23298957
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Current status of liver disease in Korea: nonalcoholic fatty liver disease.
    Park SH
    Korean J Hepatol; 2009 Dec; 15 Suppl 6():S34-9. PubMed ID: 20037278
    [TBL] [Abstract][Full Text] [Related]  

  • 16. How should we manage patients with non-alcoholic fatty liver disease in 2007?
    Chan HL; de Silva HJ; Leung NW; Lim SG; Farrell GC;
    J Gastroenterol Hepatol; 2007 Jun; 22(6):801-8. PubMed ID: 17565632
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Review article: current management of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis.
    Younossi ZM
    Aliment Pharmacol Ther; 2008 Jul; 28(1):2-12. PubMed ID: 18410557
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Liver alanine aminotransferase, insulin resistance and endothelial dysfunction in normotriglyceridaemic subjects with type 2 diabetes mellitus.
    Schindhelm RK; Diamant M; Bakker SJ; van Dijk RA; Scheffer PG; Teerlink T; Kostense PJ; Heine RJ
    Eur J Clin Invest; 2005 Jun; 35(6):369-74. PubMed ID: 15948897
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Increased prevalence of cardiovascular disease in Type 2 diabetic patients with non-alcoholic fatty liver disease.
    Targher G; Bertolini L; Padovani R; Poli F; Scala L; Tessari R; Zenari L; Falezza G
    Diabet Med; 2006 Apr; 23(4):403-9. PubMed ID: 16620269
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Non-alcoholic fatty liver disease (NAFLD): why you should care, when you should worry, what you should do.
    Lebovics E; Rubin J
    Diabetes Metab Res Rev; 2011 Jul; 27(5):419-24. PubMed ID: 21425426
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.